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 ■ INTRODUCTION
Hypertension is the leading preventable risk factor for 
premature death worldwide (1). Stroke is the third leading risk 
factor for death in most Western developed countries (2), but 
it has become the most common cause of death in China along 
with the development in social economy (3). After adjustment 
for age, the mortality of stroke was approximately 115 per 
100,000 person-years in China (4).
Hypertension and stroke are both multifactorial disorders that 
are affected by environmental factors, genetic alterations and gene-
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OBJECTIVES: Cystathionine β-synthase is a major enzyme in the metabolism of plasma homocysteine. 
Hyperhomocysteinemia is positively associated with hypertension and stroke. The present study was performed 
to examine the possible effects of Cystathionine β-synthase promoter methylation on the development of 
hypertension and stroke.
METHODS: Using quantitative methylation-specific PCR, we determined the Cystathionine β-synthase methylation 
levels in 218 healthy individuals and 132 and 243 age- and gender-matched stroke and hypertensive patients, 
respectively. The relative changes in Cystathionine β-synthase promoter methylation were analyzed using the 
2-ΔΔCt method. The percent of the methylated reference of Cystathionine β-synthase was used to represent the 
Cystathionine β-synthase promoter methylation levels.
RESULTS: In this study, the Cystathionine β-synthase promoter methylation levels of hypertensive and stroke 
participants were both higher than that of the healthy individuals (median percentages of the methylated reference 
were 50.61%, 38.05% and 30.53%, respectively, all p<0.001). Multivariable analysis showed that Cystathionine 
β-synthase promoter hypermethylation increased the risk of hypertension [odds ratio, OR (95% confidence interval, 
CI)=1.035 (1.025–1.045)] and stroke [OR (95% CI)=1.015 (1.003–1.028)]. The area under the curve of Cystathionine 
β-synthase promoter methylation was 0.844 (95% CI: 0.796–0.892) in male patients with hypertension and 0.722 
(95% CI: 0.653–0.799) in male patients with stroke.
CONCLUSION: Cystathionine β-synthase promoter hypermethylation increases the risk of hypertension and stroke, 
especially in male patients.
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environment interactions (5,6). Epigenetic modifications of the 
genome were also shown to be involved in the pathophysiological 
course of hypertension and stroke (7). DNA methylation is one 
of the most common epigenetic modifications and is primarily 
involved in control of gene expression (8). Promoter DNA that is 
highly methylated may cause transcriptional silencing of genes, 
while DNA with little methylation may result in the promotion 
of gene transcription (9). Abnormal methylation levels of ADD1 
(10), ACE (11), and AGTR1 (12) were associated with the 
pathogenesis of hypertension. Aberrant DNA methylation levels 
of LINE-1 (13), AS (14) and ABCB1 (15) have been associated 
with the development of stroke.
Cystathionine β-synthase (CBS) is a cytosolic homotetramer 
composed of 63 kDa subunits, and as a key enzyme involved 
in the metabolism of plasma homocysteine (Hcy), it mainly 
converts Hcy and serine to cysteine (16). A study of the American 
population demonstrated that the CBS gene was related to 
abnormal Hcy levels (17). Low levels of the CBS gene lead to 
hyperhomocysteinemia, which was also discovered in earlier 
studies (18, 19), indicating its effects on hypertension and stroke. 
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However, a direct association between CBS methylation and 
hypertension and stroke remains unclear.
This matched case-control study aimed to investigate the 
relationship between CBS methylation and the risk of hypertension 
and stroke in a Chinese population.
 ■ MATERIALS AND METHODS
Subjects
This matched case-control study consisted of 132 stroke 
patients, 218 healthy individuals, and 243 matched hypertensive 
patients from the Hypertension Management Information System 
in Community Health Service Centers (CHSCs) in the Nanshan 
district, Shenzhen, Guangdong Province, China. All participants 
were local residents living in Shenzhen for more than six months 
and were registered in CHSCs. The hypertensive patients were 
diagnosed based on a systolic blood pressure (SBP) ≥140 
mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg or a 
self-reported history of using antihypertensive medications (20). 
Two neurologists independently diagnosed the stroke (ischemic, 
intracerebral and subarachnoid hemorrhagic) according to WHO 
diagnostic criteria (21). Those who had a history of secondary 
hypertension, malignant tumors, liver and kidney failure, or 
pregnancy were excluded, and patients with a history of using 
vitamin B6, vitamin B12, or folic acid were also eliminated. 
All participants signed informed consent. The Research Ethical 
Committee of the Nanshan Center for Chronic Disease Control 
authorized this study.
Physical examination
All physical examinations were performed by trained 
medical staff. Physical examinations were mainly conducted 
to obtain the SBP and DBP, body mass index (BMI), waist 
circumference (WC) and hip circumference (HC). A standard 
mercury sphygmomanometer was used to measure participants’ 
SBP and DBP after sitting for at least 5 minutes. WC and HC 
were measured using inextensible anthropometric tape with the 
participations standing straight, feet positioned close together and 
arms at the sides.
Biochemical measurements
Biochemical measurements included glucose (Glu), total 
cholesterol (TC), triglycerides (TG), uric acid (UA), and plasma 
Hcy. The uricase method was used to quantitatively test the UA 
level. Enzymatic methods were adopted for the measurement 
of TC, Glu, and TG, and a circulating enzymatic method was 
employed to measure the Hcy level. All bioindicators were 
measured by an automatic biochemical analyzer (HITACH 7080, 
Tokyo, Japan).
SYBR Green-based quantitative methylation-specific 
PCR (qMSP)
The specific steps in DNA extraction and bisulfite 
conversion were performed as previously described (22). The 
details of qMSP have also been described in a previous study 
(23). The CBS gene was amplified with the following primers: 
5’-GGATGGAGTTATA TTATGAAGGT-3’ for the forward primer 
and 5’-AACAATC TCGCTCAATCG-3’ for the reverse primer. 
Simultaneously, 5’-GTGATGGAGGAGGTTTA GTAAGTT-3’ 
and 5’-CCAATAAAACCTACTCCTCCCTTAA-3’ were used 
as forward and reverse primers to amplify ACTB, respectively. 
The reaction was conducted under the following conditions: 
denaturation at 95°C for 600 sec, followed by 45 cycles at 95°C 
for 20 sec, annealing at 56°C for 45 sec and then 72°C for 20 
sec. A melting curve step was performed at 95°C for 15 sec and 
60 sec at 60˚C, with a temperature rising at 0.11°C per second 
up to 95°C to measure the fluorescence signal. The percentage of 
methylated reference (PMR) of the CBS was used to quantitate 
CBS methylation.
Statistical analysis
The mean±standard deviation (SD) and t-test/ANOVA were 
used to present and analyze continuous variables. Frequencies 
(percentages) and Chi-squared tests were used to express and 
analyze categorical variables. Odds ratios (ORs) and 95% 
confidence intervals (CIs) were calculated to estimate the risk 
of different factors in hypertension and stroke with logistic 
regression models. In stratified analysis, potential modifiers, 
such as sex (male or female), age (<65 or ≥65 years), BMI 
(<24 or ≥24 kg/m2), homocysteinemia (<15 or ≥15 μmol/l), 
smoking (yes/no), and drinking (yes/no), were assessed. The 
interaction between the PMR-CBS and stratified factors was 
examined after adjustment for age, sex, BMI, Hcy, UA, TG, TC, 
Glu, WC, HC, SBP, DBP, drinking history and smoking history. 
Pearson’s correlation analyses was performed to evaluate the 
relation between CBS methylation level and age. We used the area 
under the curve (AUC) to evaluate the diagnostic value of CBS 
methylation for hypertension and stroke. All statistical analyses 
were conducted by SPSS version 18.0 (SPSS, Inc., Somers, NY, 
USA). A two-sided p<0.05 was significant.
 ■ RESULTS
A total of five CpG sites were selected from a fragment on the 
CBS promoter (Figure 1A). Bisulfite conversion by sequencing 
the converted DNA samples showed good results (Figure 1B). 
This case-control study recruited 132 stroke patients, 218 age- 
and gender-matched healthy individuals and 243 matched 
hypertensive patients.
Table 1 shows no significant differences in age, gender, UA, 
TG, TC, and smoking status of different groups, whereas the 
PMR level of CBS was higher in hypertension and stroke patients 
than in healthy controls (mean PMRs were 50.61%, 38.05% and 
30.53%, respectively, p<0.001). The CBS promoter methylation 
levels of male subjects in the healthy control, hypertensive 
and stroke groups were significantly different (mean PMRs 
were 17.50%, 47.70%, and 32.18%, respectively, p<0.001, 
Figure 2), and those of female subjects were not significantly 
different (p=0.142). The CBS promoter methylation in males 
was lower than that in females (all p<0.001). The mean Hcy 
levels in the hypertension and stroke groups were 16.97 μmol/L 
and 21.13 μmol/L, respectively, higher than 14.57 μmol/L in 
the healthy control group (p<0.001). BMI, Glu, WC, HC, SBP 
and DBP in the hypertension and stroke groups were also higher 
than those in the healthy controls (all p<0.05). The status of 
antihypertensive drugs in stroke was also better than that in 
hypertension (p=0.008).
As shown in Table 2, multivariable logistic regression analysis 
indicated that CBS promoter hypermethylation significantly 
increased the risk of hypertension and stroke, and the ORs 
(95% CI) were 1.035 (1.025–1.045) and 1.015 (1.003–1.028), 
respectively. In addition, Hcy was related to the development 
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of hypertension and stroke, and the ORs (95% CI) were 1.040 
(1.004–1.084) and 1.081 (1.035–1.129), respectively.
Potential effect modification of the association of 
CBS promoter methylation with hypertension and stroke 
by age, gender, BMI, Hcy, drinking and smoking history 
were examined in subgroups analyses, while significant 
effect modification was observed by gender in patients with 
hypertension (p-values for interaction<0.001) and gender in 
Figure 1 - Methylation assay of the CBS gene and its quality control. (A) The abridged general view of five CpG sites on the CBS gene 
promoter. F: forward primer; R: reverse primer. The genomic positions and functional annotations of CBS were obtained from the UCSC 
genome browser according to human 2013 (GRCh37/hg19). (B) Methylation status of the CBS gene in patients with hypertension was 
analyzed by quantitative methylation-specific PCR.
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patients with stroke (p-value for interaction=0.035, Table 3). 
CBS promoter hypermethylation increased the risk of male 
hypertensive patients (OR=1.057; 95% CI = 1.041–1.073), 
male stroke patients (OR: 1.028; 95% CI: 1.011–1.044), female 
hypertensive patients (OR: 1.011; 95% CI: 0.996–1.026) and 
female stroke patients (OR: 0.992; 95% CI: 0.970–1.015). 
Table 1 - Baseline characteristics of healthy controls, hypertensive patients, and stroke patients.
Healthy controls  Hypertensive patients Stroke patients  F/χ2 p 
Age (y) 64.35 ± 9.22 66.19 ± 9.84 65.77 ± 9.32 2.28 0.103
Gender (M/F) 138/80 143/100 78/54 1.10 0.576
Hcy (μmol/L) 14.57 ± 5.70 16.97 ± 12.89 21.13 ± 18.56 11.31 <0.001
UA (μmol/L) 365.89 ± 97.06 364.50 ± 97.67 365.91 ± 87.25 0.02 0.985
TG (mmol/L) 1.75 ± 1.47 1.92 ± 1.63 1.79 ± 0.91 0.92 0.401
TC (mmol/L) 5.12 ± 1.02 5.11 ± 1.03 4.91 ± 1.07 2.00 0.137
BMI (kg/m2) 23.46 ± 3.08 24.44 ± 2.93* 24.49 ± 2.78* 7.82 0.001
Glu (mmol/L) 4.96 ± 0.81 5.67 ± 1.34* 5.64 ± 1.07* 27.33 <0.001
WC (cm) 84.69 ± 9.80 87.03 ± 9.00* 87.11 ± 10.38* 4.18 0.016
HC (cm) 93.62 ± 9.54 95.69 ± 7.99* 95.15 ± 9.63 3.22 0.041
SBP (mmHg) 123.57 ± 13.81 134.43 ± 16.47* 135.69 ± 15.86* 37.40 <0.001
DBP (mmHg) 77.95 ± 8.43 82.59 ± 11.18* 82.76 ± 11.27* 14.41 <0.001
Smoking (no/yes) 182/36 214/29 115/17 2.15 0.341
Drinking (no/yes) 136/82 176/67 112/20 20.53 <0.001
Antihypertensive drugs 
(no/yes)
- 50/193 13/119# 7.04 0.008
PMR-CBS (%) 30.53 ± 26.91 50.61 ± 25.73* 38.05 ± 24.66*# 34.93 <0.001
Hcy: plasma homocysteine, UA: uric acid, TG: triglycerides, TC: total cholesterol, BMI: body mass index, Glu: blood glucose, WC: waist circumference, HC: 
hip circumference, SBP: systolic blood pressure, DBP: diastolic blood pressure, PMR: percent of methylated reference.
*p<0.05, compared with healthy controls. 
#p<0.05, compared with hypertensive patients.
Table 2 - Association of CBS methylation and the risk of hypertension and stroke adjusted by multivariable logistic regression models.
Hypertension  Stroke 
Variable OR 95% CI OR 95% CI
CBS methylation 1.035 1.025-1.045 1.015 1.003-1.028
Gender (F/M) 0.840 0.454-1.554 1.049 0.500-2.200
Age (y) 1.001 0.972-1.030 0.995 0.963-1.028
Hcy (μmol/L) 1.040 1.004-1.084 1.081 1.035-1.129
UA (μmol/L) 0.999 0.997-1.002 1.000 0.996-1.003
TG (mmol/L) 0.902 0.739-1.102 0.830 0.603-1.142
TC (mmol/L) 0.969 0.746-1.259 0.760 0.565-1.021
BMI (kg/m2) 1.071 0.964-1.190 0.969 0.929-1.011
WC (cm) 0.972 0.935-1.011 0.969 0.929-1.011
HC (cm) 1.034 1.003-1.066 1.017 0.980-1.055
SBP (mmHg) 1.051 1.032-1.071 1.051 1.026-1.077
DBP (mmHg) 1.039 1.014-1.065 1.017 0.984-1.051
Glu (mmol/L) 2.227 1.651-3.004 2.233 1.597-3.122
Drinking (yes/no) 0.708 0.499-1.003 0.369 0.220-0.618
Smoking (yes/no) 1.204 0.555-2.612 1.073 0.427-2.693
Hcy: plasma homocysteine, UA: uric acid, TG: triglycerides, TC: total cholesterol, BMI: body mass index, Glu: blood glucose, WC: waist circumference, 
HC: hip circumference, SBP: systolic blood pressure, DBP: diastolic blood pressure, PMR: percent of methylated reference, OR: odds ratios, 95% CI: 95% 
confidence intervals.
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Subsequently, we performed correlation tests between PMR 
levels of CBS and clinical variables in healthy subjects, and the 
results showed a positive correlation between the PMR level 
of the CBS promoter and age (r=0.17, p=0.046, Figure 3) in 
healthy male controls.
ROC curves were generated to evaluate the role of the PMR 
level of CBS in the diagnostic value of hypertension and stroke. 
The AUC of CBS promoter methylation was 0.844 (95% CI, 
0.796–0.892) in male hypertensive patients and 0.722 (95% CI, 
0.653–0.799) in male stroke patients (Figure 4).
 ■ DISCUSSION
The purpose of the present matched study was to examine 
the risk of abnormal CBS methylation in hypertensive and stroke 
patients. The results revealed that CBS promoter hypermethylation 
Table 3 - Multivariate-adjusted odds ratios and 95% confidence intervals of hypertension and stroke for CBS methylation in subgroups.
Hypertension  Stroke 
OR (95% CI)* p-interaction OR (95% CI)* p-interaction
Gender <0.001 0.007
Men 1.057 (1.041-1.073) 1.028 (1.011-1.044)
Women 1.011 (0.996-1.026) 0.992 (0.970-1.015)
Age 0.635 0.836
<65 y 1.037 (1.019-1.056) 1.013 (0.989-1.037)
≥65 y 1.038 (1.025-1.052) 1.021 (1.005-1.037)
BMI 0.325 0.951
<24 kg/m2 1.038 (1.023-1.054) 1.014 (0.996-1.032)
≥24 kg/m2 1.037 (1.023-1.052) 1.019 (1.000-1.038)
Homocysteinemia 0.191 0.932
<15 μmol/L 1.032 (1.019-1.044) 1.014 (0.997-1.031)
≥15 μmol/L 1.050 (1.031-1.071) 1.020 (0.999-1.042)
Drinking 0.761 0.459
No 1.031 (1.020-1.042) 1.016 (1.002-1.029)
Yes 1.060 (1.033-1.087) 1.015 (0.981-1.051)
Smoking 0.861 0.794
No 1.036 (1.025-1.047) 1.014 (1.001-1.027)
Yes 1.077 (1.026-1.131) 0.945 (0.854-1.044)
OR: odds ratios, 95% CI: 95% confidence intervals.
*Adjusted for age, sex, BMI, homocysteine, uric acid, triglycerides, total cholesterol, plasma glucose, waist circumference, hip circumference, systolic blood 
pressure, diastolic blood pressure, drinking and smoking.
Figure 2 - Comparison of CBS methylation levels between healthy controls and hypertensive and stroke patients.
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Figure 4 - Receiver operating characteristic (ROC) curve of CBS methylation in male hypertensive and stroke patients.
Figure 3 - Pearson correlation between age and CBS methylation in male healthy controls.
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was an independent risk factor for hypertension and stroke, 
especially in men. ROC curve analysis also suggested that CBS 
promoter hypermethylation was a potential biomarker in male 
subjects for the diagnosis of hypertension and stroke.
Accumulating evidence, as well as our findings, indicates 
that Hcy may be related to hypertension and stroke (24). The 
CBS enzyme, one of three predominant enzymes, is involved in 
the process of Hcy conversion to cysteine and contributes nearly 
40–50% of cysteine production (25). CBS deficiency was identified 
as a genetic factor that resulted in elevated levels of Hcy or 
hyperhomocysteinemia (25). Hypermethylation levels of the CBS 
gene were observed in hypertension and stroke patients, which 
might lead to silencing of CBS gene expression and accumulation 
of Hcy levels, thus contributing to the susceptibility to hypertension 
and stroke. In addition, the PMR level of CBS was lower in stroke 
patients than hypertensive patients. In acute ischemic stroke 
conditions, CBS expression was activated and increased, causing 
increased production of H2S (26,27). CBS gene transfection 
of SH-SY5Y cells would results in production of enzymes to 
synthesize H2S, which would enhance cell death and exacerbate 
ischemic injuries (26).
The difference in CBS methylation levels was statistically 
significant only in males, and gender differences were observed 
in several genes (28, 29). Renal CBS enzyme levels in C57BL/6J 
mice were higher in males than females (30). Males and females 
had different susceptibilities to hypertension, and males were more 
susceptible (31). Sexual dimorphism in mammalian gene expression 
is thought to result in different sex hormone (testosterone, 
androgens) levels in males and females (32). Testosterone has 
a distinct impact on renal CBS enzyme levels, and when female 
mice were injected with androgen, the renal CBS activity increased 
twofold (33). Androgens mainly regulate renal CBS levels by 
complex organ-specific regulation (30).
Additionally, age had a positive correlation with promoter 
hypermethylation (34), and methylation levels in several genes were 
shown to increase with aging (34,35). Our study also demonstrated 
a similar association between age and CBS methylation in males. 
However, we adjusted for age by multivariable logistic regression 
analysis and confirmed that the PMR level of CBS was an 
independent risk factor both in hypertension and stroke.
To the best of our knowledge, the present work is the first study 
with a large samples size to assess the influence of CBS methylation 
on hypertension and stroke. In addition, as this is a matched case-
control study, the influence of age on methylation levels was 
controlled. However, the following limitations should be noted. First, 
the genetic ancestry link is different in different ethnic groups and has 
a major impact on the DNA methylation level, leading to differences 
in individual risk to diseases (36,37). Because the subjects enrolled 
in this study were only Chinese Han individuals from Shenzhen, our 
conclusion might not be applicable to other ethnic groups. Second, 
only the PMR level of the CBS gene was measured, and DNA 
methylation of other genes involved in Hcy metabolism may also 
confer susceptibility to hypertension and stroke. Third, we did not 
perform gene expression analysis, and the conclusions of our study 
are not causal. Finally, although we adjusted for confounding factors 
that may affect the PMR level of CBS, potential confounding factors 
such as medical treatment (38) may have an effect.
In conclusion, male patients with hypertension and stroke had 
increased CBS methylation levels. In Chinese Han males, CBS 
hypermethylation in the blood might serve as an independent 
biomarker for the diagnosis of hypertension and stroke. Further 
large-scale studies in different races with gene expression analyses 
should be performed to verify our findings.
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